Article Text

PDF
G513 Seizure management in end-of-life care for children
  1. N Harris1,
  2. M Baba2,
  3. A Beringer1,
  4. C Mellor3,
  5. R Rogers3,
  6. K Taylor4,
  7. PM Sharples3
  1. Centre for Health and Clinical Research, University of the West of England, Bristol, UK
  2. Charlton Farm, Children’s Hospice South West, Wraxall, UK
  3. Bristol Royal Hospital for Children, United Hospitals Bristol NHS Trust, Bristol, UK
  4. Children’s Integrated Services Team, Devon VirginCare, Exeter, UK

Abstract

Background Controlling seizures in children approaching death is often challenging. The evidence base to guide best practice is limited. We compared current practice in our region against the guidance for seizure management produced by the Association of Paediatric Palliative Medicine (APPM), seeking to identify any difficulties, barriers, and areas for improvement in symptom control.

Methods Retrospective case note review of episodes of challenging seizure management in children receiving end-of-life care over a ten year period (2006–2015).

Results We identified and reviewed eighteen cases. Six (33%) had a malignancy, eight (44%) had a progressive neurodegenerative condition, and four (22%) had a static neurological condition with associated epilepsy. Fifteen (83%) had seizures during their final admission/care episode, and the remaining three had had status epilepticus previously and were felt to be at high risk of recurrence. Thirteen (72%) died in their local hospice, four (22%) at home, and one (6%) in hospital. Seventeen (94%) involved the use of subcutaneous or intravenous midazolam infusion, for a mean of eleven days (range 3–27). There was a wide range of starting doses of midazolam, and 9/17 (53%) received final doses in excess of APPM dose recommendations. Six individuals (33%) received subcutaneous phenobarbital infusions, with four of these (67%) receiving final doses in excess of APPM dose recommendations. Plans for adjustments of infusion rates, maximal doses, or alternative approaches should treatment fail, were inconsistent. In 17/18 (94%) cases seizures were successfully controlled in the days or hours before the child died, but this was sometimes a prolonged process. Fear of apnoea or over-sedation were the main barriers to prompt symptom control. Staff found the experience of managing seizures at end-of-life challenging and stressful.

Conclusions Pharmacological approaches to seizure management in end-of-life care are variable, often exceeding dose recommendations. Despite this, safe and effective seizure control was reported to be possible in all settings. Best-practice management guidance should be developed to support improved care and to increase staff confidence in this area.

Project funded by Health Education England

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.